Microscopic Polyangiitis
Microscopic Polyangiitis (MPA) is a rare autoimmune condition that causes blood vessel inflammation (vasculitis), restricting blood flow, and lead to organ damage.
&nbsp;
Microscopic Polyangiitis Epidemiology Segmentation
&nbsp;
<ul>
<li class="ql-align-justify">Total Incident Cases of Microscopic Polyangiitis</li>
<li class="ql-align-justify">Gender-specific Microscopic Polyangiitis Incident Cases</li>
<li class="ql-align-justify">Age-specific Microscopic Polyangiitis Incident Cases</li>
</ul>
&nbsp;
<a style="color: #0047b2;" href="https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Microscopic Polyangiitis Epidemiological Insights</a> Observed in 2020
&nbsp;
<ul>
<li class="ql-align-justify">The total Microscopic Polyangiitis incident cases were found to be 5,196 in the 7MM countries.</li>
<li class="ql-align-justify">In 2020, 660 MPA incident cases were observed in males, whereas 325 MPA incident cases were observed in females in the US.</li>
<li class="ql-align-justify">In 2020, 121 MPA incident cases were observed in the age group 0-17 years, whereas 864 MPA incident cases were observed in age group &ge;18 years in the US.</li>
</ul>
&nbsp;
<a style="color: #0047b2;" href="https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market" target="_blank" rel="noopener noreferrer">Microscopic Polyangiitis Market Insight</a>
&nbsp;
The Microscopic Polyangiitis market size was found to be USD 31 million in the 7MM in 2020.
&nbsp;
Microscopic Polyangiitis Market Drivers
&nbsp;
<ul>
<li class="ql-align-justify">Companies shifting their focus to this area</li>
<li class="ql-align-justify">Ubiquitous incidence</li>
<li class="ql-align-justify">Increasing approvals by regulatory bodies</li>
<li class="ql-align-justify">Rising development of new treatments</li>
</ul>
&nbsp;
Microscopic Polyangiitis Market Barriers
&nbsp;
<ul>
<li class="ql-align-justify">Associated side effects with current treatment</li>
<li class="ql-align-justify">Limitations associated with the only approved drug</li>
<li class="ql-align-justify">Delay in diagnosis due to lacking specific diagnostic procedure</li>
</ul>
&nbsp;
Microscopic Polyangiitis Emerging Drugs
&nbsp;
The emerging drugs in the Microscopic Polyangiitis market are
&nbsp;
<ul>
<li class="ql-align-justify">Vilobelimab (IFX-1, CaCP290)</li>
<li class="ql-align-justify">Vynpenta (Avacopan, CCX168)</li>
<li class="ql-align-justify">Belimumab</li>
<li class="ql-align-justify">GGS-MPA (Freeze-dried Sulfonated Human Immunoglobulin), and several others</li>
</ul>
&nbsp;
Key Microscopic Polyangiitis Companies
&nbsp;
The key companies working in the Microscopic Polyangiitis market are
&nbsp;
<ul>
<li class="ql-align-justify">InflaRx GmbH</li>
<li class="ql-align-justify">ChemoCentryx</li>
<li class="ql-align-justify">Kissei Pharmaceutical</li>
<li class="ql-align-justify">Vifor Pharma</li>
<li class="ql-align-justify">GlaxoSmithKline</li>
<li class="ql-align-justify">Teijin Pharma, and several others</li>
</ul>

Microscopic Polyangiitis Market

Microscopic Polyangiitis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape.